GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Debt-to-EBITDA

Ardelyx (Ardelyx) Debt-to-EBITDA : -1.20 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ardelyx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.3 Mil. Ardelyx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $100.6 Mil. Ardelyx's annualized EBITDA for the quarter that ended in Mar. 2024 was $-87.6 Mil. Ardelyx's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -1.20.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ardelyx's Debt-to-EBITDA or its related term are showing as below:

ARDX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2   Med: -0.61   Max: -0.3
Current: -2

During the past 12 years, the highest Debt-to-EBITDA Ratio of Ardelyx was -0.30. The lowest was -2.00. And the median was -0.61.

ARDX's Debt-to-EBITDA is ranked worse than
100% of 274 companies
in the Biotechnology industry
Industry Median: 1.355 vs ARDX: -2.00

Ardelyx Debt-to-EBITDA Historical Data

The historical data trend for Ardelyx's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Debt-to-EBITDA Chart

Ardelyx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.63 -0.62 -0.30 -0.60 -1.01

Ardelyx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.61 0.94 -0.55 -1.20

Competitive Comparison of Ardelyx's Debt-to-EBITDA

For the Biotechnology subindustry, Ardelyx's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ardelyx's Debt-to-EBITDA falls into.



Ardelyx Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ardelyx's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.435 + 51.547) / -55.354
=-1.01

Ardelyx's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.314 + 100.612) / -87.616
=-1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Ardelyx  (NAS:ARDX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ardelyx Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ardelyx's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ardelyx (Ardelyx) Business Description

Traded in Other Exchanges
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Executives
David P. Rosenbaum officer: Chief Development Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Justin A Renz officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer officer: See Remarks 78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks officer: See Remarks C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
Laura A Williams officer: Chief Medical Officer 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Robert Ora Felsch officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Michael Raab director, officer: President & CEO 1119 ST PAUL STREET, BALTIMORE MD 21202
Susan Rodriguez officer: Chief Commercial Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Jeffrey W Jacobs officer: VP, Chemistry C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli officer: See Remarks C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010